Research & Education

IASLC European Webinar Series - 2015/2016 - Biomarkers and Personalized Medicine for Patients with Lung Cancer

Thursday, July 14, 2015 - 6 p.m. BST - Recording Available

 

 Keith Kerr

Keith Kerr, BSc, MB, ChB, FRC Path, FRCPE
Consultant Pathologist
Honorary Chair in Pulmonary Pathology
University of Aberdeen
Scotland

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

      Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Biomarkers and Personalized Medicine for Patients with Lung Cancer

Date of Activity:

 

07/14/2015

Faculty/Speaker(s):

Financial DISCLOSURES

 

Keith Kerr, BSc, MB, ChB, FRC Path, FRCPE- Speaker-

 

CONSULTANT: AstraZeneca, Roche, Genentech, Eli Lilly, Pfizer, Novartis, Boehringer Ingelheim, Bristol-Meyers Squibb, Merck and Clovis.

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)

 Internet Enduring Material

Are there Commercial Supporters for this activity?

        Yes     

If yes, please list: Unrestricted grant from: Celgene and Bristol-Meyers Squibb

In this session, Prof. Keith Kerr updates a webinar first presented last year, on developments in personalized medicine for patients with lung cancer, the impact that this has had, and could have in the future, for those patients, and how the pursuit of biomarkers to predict response to targeted therapy has changed lung cancer diagnostics. This has implications not only for surgical pathologists and molecular pathologists but also for oncologists and any specialist involved in obtaining tissue for lung cancer diagnosis.

The presentation will briefly discuss the diagnostic approach to lung cancer samples with relevance to personalized therapy, the status of EGFR and ALK testing, introduce the plethord and possible new biomarkers that may be required in the future, including the prospects for biomarkers in immunotherapy, and discuss the practical implication of providing this service.

After viewing this program attendees will:

  1. Describe the diagnostic approach to lung cancer samples to personalize treatment of patients
  2. Illustrate the status of current biomarker testing as well as possible new biomarker testing
  3. Demonstrate the practical implications of biomarker evaluation for the multi-disciplinary treatment team

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

This webinar updates a webinar first presented last year, on developments in personalized medicine for patients with lung cancer, the impact that this has had, and could have in the future, for those patients, and how the pursuit of biomarkers to predict response to targeted therapy has changed lung cancer diagnostics. This has implications not only for surgical pathologists and molecular pathologists but also for oncologists and any specialist involved in obtaining tissue for lung cancer diagnosis.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

Download Recording

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Letter of Agreement (LOA)

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Tuesday, July 14, 2015 at 1:00:00 PM EDT UTC-4 hours
Denver (U.S.A. - Colorado) Tuesday, July 14, 2015 at 11:00:00 AM MDT UTC-6 hours
Glasgow (Scotland) Tuesday, July 14, 2015 at 6:00:00 PM BST UTC+1 hour
Paris (France) Tuesday, July 14, 2015 at 7:00:00 PM CEST UTC+2 hours 
Rome (Italy) Tuesday, July 14, 2015 at 7:00:00 PM CEST UTC+2 hours
Brussels (Belgium) Tuesday, July 14, 2015 at 7:00:00 PM CEST UTC+2 hours
Moscow (Russia) Tuesday, July 14, 2015 at 8:00:00 PM MSK UTC+3 hours
Amsterdam (Netherlands) Tuesday, July 14, 2015 at 7:00:00 PM CEST UTC+2 hours
Dublin (Ireland) Tuesday, July 14, 2015 at 6:00:00 PM IST UTC+1 hour
Los Angeles (U.S.A.) Tuesday, July 14, 2015 at 10:00:00 AM PDT UTC-7 hours
Corresponding UTC (GMT) Tuesday, July 14, 2015 at 5:00:00 PM     

How to use the Time Zone Converter

This series is supported in part by unrestricted educational grants provided by Bristol-Myers Squibb Co., Celgene and Genentech